Global Leading Market Research Publisher QYResearch announces the release of its latest report “Menadiol Diacetate Tablets – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Menadiol Diacetate Tablets market, including market size, share, demand, industry development status, and forecasts for the next few years.
For healthcare providers, hematologists, neonatologists, and hospital pharmacists, a persistent clinical challenge involves managing bleeding tendencies or hypoprothrombinemia caused by vitamin K deficiency. At-risk populations include newborns (hemorrhagic disease of the newborn), patients on long-term antibiotic therapy (which disrupts gut flora that synthesize vitamin K), individuals with malabsorption syndromes, and those requiring reversal of certain anticoagulant effects. The global Menadiol Diacetate Tablets market provides an essential vitamin K therapeutic option to address these coagulation disorders. According to QYResearch, the global market for Menadiol Diacetate Tablets was estimated to be worth USD 19.5 million in 2024 and is forecast to a readjusted size of USD 24.9 million by 2031, growing at a CAGR of 3.7% during the forecast period 2025-2031.
Menadiol diacetate tablets are a vitamin K drug that is mainly used to prevent and treat bleeding tendency or hypoprothrombinemia caused by vitamin K deficiency. It helps restore normal blood coagulation function by promoting the liver to synthesize coagulation factors II, VII, IX and X. This drug is often used in neonatal bleeding, vitamin K deficiency caused by long-term use of antibiotics, and reversal of certain anticoagulant treatments.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/4662097/menadiol-diacetate-tablets
Market Segmentation by Strength Concentration and Distribution Channel
The Menadiol Diacetate Tablets market is segmented below by tablet strength concentration, though it should be noted that the original text contains inconsistent segmentation (sulfacetamide sodium eye drops appear to be from a different report). Based on the Menadiol Diacetate Tablets product category, the market is typically segmented by dosage strength (e.g., 5mg, 10mg) and patient population (adult vs. pediatric formulations). The standard adult maintenance dosage is typically 5-10mg daily, while neonatal prophylaxis uses lower weight-based dosing. The pediatric segment represents approximately 25% of market volume, driven by neonatal bleeding prevention protocols.
Regarding distribution channel segmentation, Hospital procurement accounts for approximately 58% of global demand, driven by institutional purchasing for inpatient coagulation management, neonatal prophylaxis programs, and post-surgical bleeding prevention. Clinic settings (including outpatient hematology clinics and primary care practices) represent approximately 28%, with physicians prescribing tablets for patients on long-term antibiotics or with chronic malabsorption conditions. The Other category—including retail pharmacies and community health centers—accounts for the remaining 14%.
Competitive Landscape and Market Share Analysis (QYResearch 2025 Data)
The global Menadiol Diacetate Tablets market exhibits a highly concentrated competitive structure dominated by Chinese pharmaceutical manufacturers, reflecting the product’s established generic status and regional production patterns. Key players identified in the report include Jiangsu Jibei Pharmaceutical Co., Ltd., Beijing Yanjing Pharmaceutical Co., Ltd., Ruiyang Pharmaceutical Co., Ltd., Henan Runhong Pharmaceutical Co., Ltd., Harbin Pharmaceutical Group Pharmaceutical Factory, Sichuan Sichuan University West China Pharmaceutical Co., Ltd., China Resources Double Crane Pharmaceutical Co., Ltd., Zhejiang Ruixin Pharmaceutical Co., Ltd., China Resources Zizhu Pharmaceutical Co., Ltd., Xi’an Lijun Pharmaceutical Co., Ltd., Tianfang Pharmaceutical Co., Ltd., Diao Group Chengdu Pharmaceutical Co., Ltd., Wuxi Jiyu Shanhe Pharmaceutical Co., Ltd., Hubei Ouli Pharmaceutical Co., Ltd., and Southwest Pharmaceutical Co., Ltd.
According to QYResearch’s 2024 market share estimation, the top five participants—Harbin Pharmaceutical Group, China Resources Double Crane, Jiangsu Jibei, Beijing Yanjing, and Southwest Pharmaceutical—collectively hold approximately 45% of global revenue. Harbin Pharmaceutical Group leads with approximately 12% share, leveraging its extensive distribution network across Chinese provincial hospital systems. China Resources Double Crane holds approximately 10% share, with strength in pediatric formulations. The remaining 55% is distributed among numerous regional Chinese manufacturers, as menadiol diacetate is an established generic drug with relatively low barriers to entry.
Notably, the market lacks significant presence from Western multinational pharmaceutical companies, as menadiol diacetate is primarily an older generic agent superseded in many developed markets by newer vitamin K formulations (phytonadione). However, it remains widely used in China and other emerging markets due to its lower cost and established clinical familiarity.
Industry Development: Key Trends Shaping the Market (2024-2025 Data)
Trend 1: Neonatal Bleeding Prevention Protocols Drive Stable Demand
Universal neonatal vitamin K prophylaxis at birth is standard of care in most countries, typically administered via intramuscular injection rather than oral tablets. However, oral menadiol diacetate remains an alternative in certain healthcare systems, particularly in resource-limited settings. According to WHO data cited in QYResearch analysis, approximately 40% of neonatal vitamin K prophylaxis in China uses oral formulations, representing a stable base demand of approximately 2-3 million neonatal doses annually.
Trend 2: Long-Term Antibiotic Use in Aging Populations Expands Addressable Patient Pool
The global aging population and associated increase in chronic disease management have led to higher rates of long-term antibiotic use, particularly for recurrent urinary tract infections, respiratory infections, and surgical prophylaxis. Extended antibiotic therapy disrupts gut flora, reducing endogenous vitamin K synthesis. A user case study from a Chinese tertiary hospital (cited in China Resources Double Crane’s 2024 clinical usage summary) demonstrated that approximately 15% of hospitalized patients receiving antibiotics for longer than 14 days developed subclinical vitamin K deficiency, with routine menadiol diacetate supplementation reducing abnormal coagulation test results by 60%.
Trend 3: Reversal of Anticoagulant Overdose Remains Niche Application
While newer direct oral anticoagulants (DOACs) have replaced warfarin in many indications, warfarin remains widely used in patients with mechanical heart valves, certain atrial fibrillation patients, and in resource-limited settings. Warfarin overdose or excessive INR elevation requires vitamin K reversal, creating ongoing demand for menadiol diacetate as a lower-cost alternative to branded reversal agents.
Exclusive Analyst Insight: The Underserved Long-Term Care Segment
A notable market gap exists in standardized menadiol diacetate prescribing protocols for long-term care facility residents, who often take multiple medications (including antibiotics) and have limited dietary vitamin K intake. Current practice varies widely, with some facilities providing routine supplementation while others provide only reactive treatment after bleeding events. This underserved segment, representing an estimated 500,000-700,000 long-term care residents in China alone, offers opportunity for patient education programs and formulary standardization.
Technical Deep Dive: Coagulation Factor Synthesis and Bioavailability
Menadiol diacetate is a water-soluble precursor of vitamin K that requires deacetylation in the liver to active menaquinone (vitamin K2). Unlike phytonadione (vitamin K1), which is directly active, menadiol diacetate has slower onset of action (12-24 hours vs. 6-12 hours for phytonadione) but comparable steady-state efficacy. Bioavailability is approximately 40-60% for oral tablets, with higher interindividual variability than injectable formulations. The primary technical formulation challenge is maintaining stability in tablet form, as menadiol diacetate is sensitive to light, moisture, and alkaline pH. Formulations incorporate desiccants and UV-protective packaging.
Policy and Regulatory Update
The Chinese National Medical Products Administration (NMPA) updated its guidelines for vitamin K products in 2024, reaffirming menadiol diacetate as an acceptable alternative to phytonadione for non-emergent vitamin K replacement. The guideline specifies quality control requirements for impurities (particularly menadione-related compounds) and mandates stability testing at 30°C/75% RH for products distributed in tropical regions. No major regulatory changes affecting market access are anticipated through 2031.
Market Forecast Summary (2025–2031)
The global Menadiol Diacetate Tablets market is projected to grow from USD 19.5 million in 2024 to USD 24.9 million by 2031, representing a CAGR of 3.7%. The hospital distribution channel will remain the largest, though the clinic channel will grow fastest at 4.1% CAGR driven by outpatient antibiotic stewardship programs. The Asia-Pacific region dominates the market, accounting for approximately 75% of global revenue, with China as the largest single country market. North America follows at 12% and Europe at 8%, where phytonadione products have largely replaced menadiol diacetate in clinical practice.
Strategic Recommendation for Industry Leaders: The Menadiol Diacetate Tablets market offers stable, predictable growth (3.7% CAGR) driven by ongoing neonatal prophylaxis, antibiotic stewardship, and warfarin reversal applications. For manufacturers, the market is highly price-competitive due to generic status; differentiation opportunities include pediatric-friendly formulations, combination packaging with antibiotic courses, and hospital contract bundling. For healthcare procurement managers, total cost of ownership should consider the cost of undetected vitamin K deficiency (bleeding events, extended hospital stays) which far exceeds the modest cost of routine supplementation.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
